Generated September 5, 2026.
Overview
These three healthcare-focused ETFs pursue fundamentally different strategies: ARKG is an actively managed portfolio concentrated in genomics and gene-editing companies; HLTH is a newer actively managed fund targeting AI-driven healthcare applications across drug discovery, diagnostics, and medical devices; XLV is a passive index ETF tracking the broad healthcare sector, including pharmaceuticals, medical devices, insurers, and healthcare providers. The key distinction is between two narrowly focused, high-conviction active strategies versus a diversified sector benchmark.
How they differ
ARKG and HLTH target specific innovation themes within healthcare—genomics/CRISPR and AI, respectively—while XLV holds the entire S&P 500 Health Care Select Sector Index, a much wider net. This is the biggest structural difference: thematic active portfolios versus sector-wide passive exposure.
Size and track records separate them sharply. XLV is a behemoth at with roots back to 12/16/1998. ARKG, launched 10/31/2014, manages and carries a 2.37 beta, reflecting its concentration in higher-volatility genomics stocks. HLTH is brand-new—launched 07/21/2026—and micro-cap at , so it lacks performance history and meaningful liquidity.
Who each is best for
ARKG: Fits investors with high risk tolerance seeking long-term exposure to genomics and gene-therapy innovation, comfortable holding a concentrated portfolio without regular distributions and weathering significant price swings.
HLTH: Fits investors interested in artificial intelligence applications within healthcare and willing to accept very limited liquidity, minimal AUM, and no historical performance track record in exchange for a thematic bet.
XLV: Fits investors seeking broad healthcare sector exposure with dividend income, low fees, and stability across large-cap pharma, medical devices, and healthcare services.
Key risks to know
- Concentration and volatility (ARKG): ARKG focuses on genomics and gene editing, a narrow slice of healthcare. With a 2.37 of 2.38, the fund amplifies broad market moves and is especially sensitive to shifts in biotech sentiment or genomics funding cycles.
- No earnings history (HLTH): Since 07/21/2026, HLTH has no demonstrated track record. Investors cannot assess whether its AI-healthcare thesis translates to outperformance or whether the active manager's stock picks beat the index.
- Regulatory and clinical execution risk (ARKG, HLTH): Genomics and AI-driven drug discovery depend on FDA approvals, clinical trial success, and reimbursement adoption. A series of failed trials or regulatory setbacks can rapidly erode portfolio value.
- Liquidity constraints (HLTH): At , HLTH faces potential closure, forced redemptions, or closure if assets do not grow. Illiquidity also widens the bid-ask spread, raising trading costs.
- Sector rotation and index risk (XLV): XLV's 0.52 of 0.51 means it underperforms in strong equity markets and outperforms in downturns. Passive sector exposure captures no thematic upside if healthcare underperforms the broader market or if innovation migrates to fields outside XLV's index.
Bottom line
If you prioritize access to a genomics or AI-healthcare innovation theme and can tolerate concentration risk, ARKG offers ten years of active management history (though HLTH is untested and extremely illiquid). If you want broad healthcare exposure with 1.5% yield and minimal cost, XLV aligns with a diversified sector allocation. The tradeoff is thematic conviction and growth potential against breadth, stability, and income. Past performance does not predict future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
